Cargando…

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis

Hypocalcemia is the most common major adverse event in patients with osteoporosis receiving the bone resorption inhibitor denosumab; however, limited information is available regarding risk factors of hypocalcemia. Therefore, this study aimed to identify the risk factors of hypocalcemia induced by d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishikawa, Koji, Nagai, Takashi, Sakamoto, Keizo, Ohara, Kenji, Eguro, Takeshi, Ito, Hiroshi, Toyoshima, Yoichi, Kokaze, Akatsuki, Toyone, Tomoaki, Inagaki, Katsunori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147395/ https://www.ncbi.nlm.nih.gov/pubmed/27980413 http://dx.doi.org/10.2147/TCRM.S123172

Ejemplares similares

High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
por: Ishikawa, Koji, et al.
Publicado: (2018)

Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study
por: Tsuchiya, Koki, et al.
Publicado: (2021)

Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis
por: Tsuchiya, Koki, et al.
Publicado: (2019)

Risk factors predicting osteosarcopenia in postmenopausal women with osteoporosis: A retrospective study
por: Okamura, Hiroki, et al.
Publicado: (2020)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Severe Refractory Hypocalcemia Caused by Denosumab
por: Dadana, Sriharsha, et al.
Publicado: (2023)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
por: Słopień, Radosław, et al.
Publicado: (2017)

The effect of denosumab on pedicle screw fixation: a prospective 2-year longitudinal study using finite element analysis
por: Tani, Soji, et al.
Publicado: (2021)

Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence
por: Cairoli, Elisa, et al.
Publicado: (2015)

Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea
por: Kang, Jung-Yoon, et al.
Publicado: (2022)

Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer
por: Muqeet Adnan, Mohammed, et al.
Publicado: (2014)

The Calcium Culprit: A Case of Denosumab-induced Hypocalcemia
por: Kalayanamitra, Ricci, et al.
Publicado: (2019)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis
por: Gu, Hai-Feng, et al.
Publicado: (2015)

Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
por: Johnson, Ben, et al.
Publicado: (2021)

Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review
por: Nargesi, Shahin, et al.
Publicado: (2022)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Case of femoral diaphyseal stress fracture after long-term risedronate administration diagnosed by iliac bone biopsy
por: Nagai, Takashi, et al.
Publicado: (2013)

Denosumab Induced Severe Prolonged Hypocalcemia in Metastatic Prostate Cancer
por: Mehmood, Hassan, et al.
Publicado: (2021)

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
por: Watts, N. B., et al.
Publicado: (2011)

Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab
por: Scheiner, S, et al.
Publicado: (2014)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

Does the VDR gene polymorphism influence the efficacy of denosumab therapy in postmenopausal osteoporosis?
por: Wawrzyniak, Anna, et al.
Publicado: (2023)

Integrated Osteoporosis Care to Reduce Denosumab-Associated Hypocalcemia for Patients with Advanced Chronic Kidney Disease and End-Stage Renal Disease
por: Hsu, Chia-Tien, et al.
Publicado: (2023)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course
por: Strickling, Jarred, et al.
Publicado: (2019)

Denosumab-Induced Hypocalcemia after Billroth II Gastric Bypass Surgery
por: Schmucker, Abigail M., et al.
Publicado: (2020)

Hypocalcemia in a Patient With Metastatic Prostate Cancer From Denosumab Treatment
por: Gouli, Sugam, et al.
Publicado: (2021)

Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report
por: Park, S.Y., et al.
Publicado: (2021)

Denosumab Induced Severe Hypocalcemia in a Patient With Metastatic Prostate Cancer
por: Naher, Kamrun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_alnpadidr5e86cfjm90hq1ehq5